Purpose: To determine differences in the clinical characteristics and antifungal susceptibility patterns among molecularly characterized ocular Fusarium sp isolates.
Results: Fusarium solani isolates had significantly higher values of minimum inhibitory concentration for 90% isolates (MIC90) with voriconazole than F. non-solani organisms (16 and 4 mg/mL, respectively). Isolates of F. solani also exhibited a significantly longer time to cure (65 vs. 40.5 days), a worse follow-up best-corrected visual acuity (20/118 vs. 20/36) , and an increased need for urgent surgical management (7 vs. 0 penetrating keratoplasties) when compared with those of F. non-solani.
Conclusions: This is the first report to examine the correlation between ocular genotyped Fusarium sp and clinical outcomes. It supports the overall worse prognosis of F. solani versus F. non-solani isolates, including higher voriconazole resistance by the former. The clinical implementation of molecular-based diagnostics and antifungal efficacy testing may yield important prognostic and therapeutic information that could improve the management of fungal ocular infections.
Key Words: keratitis, Fusarium sp, genotyping, antifungal, clinical outcomes (Cornea 2013; 32:667-673) A fter the recent global outbreak of contact lens (CL)associated Fusarium keratitis (2005) (2006) , there has been a renewed interest and significant focus on research establishing epidemiology, classification, diagnosis, and treatment standards. It is now clear that the incidence of Fusarium keratitis has increased dramatically over the past 4 decades, accounting for up to 50% of all cases of microbial keratitis in tropical climates. [1] [2] [3] [4] [5] [6] [7] [8] [9] This increasing incidence is multifactorial, and it is believed to be because of the increased awareness and changes in risk factor profiles throughout the global population, including an increase in the use of topical steroids and antibacterial agents, as well as an increase in surgical procedures, CL use, ocular trauma, chronic ocular surface diseases, and immunocompromised patients. 6, [10] [11] [12] [13] Among the Fusarium species that are pathogenic to the eye, Fusarium solani is the most common, followed by F. oxysporum, F. dimerum, F. incarnatum-equiseti, and Gibberella fujikuroi. 14, 15 Microbiologic techniques have long served as the diagnostic gold standard in the setting of fungal keratitis. Such techniques are capable of reliably differentiating among the different molds and yeasts causing keratitis. Although highly accurate at genus identification (Fusarium, Aspergillus, Candida, etc), morphologic classification of Fusarium isolates to the species level using microbiologic techniques (F. solani, F. oxysporum, etc) is problematic and inconsistent because of the large degree of morphologic variability demonstrated at different growth stages. 15, 16 In light of the increasing incidence of Fusarium keratitis, this inconsistency in morphologic identification has generated significant interest in finding a more consistent and reliable basis for organism classification. Recent reports have demonstrated genotypic identification systems as a more accurate and reproducible means of properly identifying ocular Fusarium pathogens, 14, 17 and a clear consensus has emerged 18-21 that DNA sequence-based methods will be essential for rapid species identification of the Fusarium genus in clinical laboratories. 22 The question remains: is it clinically important to accurately differentiate between the different Fusarium species causing keratitis? Recent reports [23] [24] [25] suggest that filamentous fungi harbor unique species-specific in vitro susceptibility profiles to the existing and emerging antifungal agents. However, within the Fusarium genus and among isolates pathogenic to the eye, these species-specific antifungal susceptibility profiles have not been firmly established. 26, 27 Furthermore, although the etiology and epidemiology of Fusarium keratitis has been well studied, 3, 4, 5, 28, 29 very little has been revealed about the differences in clinical characteristics and outcomes associated with infections as a result of different Fusarium species.
In this study, we investigate and compare the in vitro susceptibility profiles and provide the first report of the clinical characteristics and outcomes among ocular pathogenic Fusarium isolates classified by genotypic analysis. Such information is useful from a prognostic, diagnostic, and therapeutic viewpoint to determine the level of pathogen identification that has the potential to directly influence practice patterns and patient outcomes.
METHODS

Isolates
Fifty-eight isolates of Fusarium sp, representing 52 patients, were retrospectively selected from the microbiology isolate library at the Bascom Palmer Eye Institute based on the morphologic species classification to include approximately 20 isolates of each F. solani, F. oxysporum, and F. species without further designation. We included consecutive isolates from May 2005 to June 2007. In addition, this group of isolates was supplemented with samples dating back to April 2000 to achieve the desired equal distribution from each morphologic designation. The source distribution of the isolates was cornea (41), aqueous humor (4), vitreous (1), CL (8) , and CL case (4) . A recent article from our group 15 explains in detail the genotyping procedures, conforming to the most recent Fusarium species complexes classification system. 14, 21 The quality control reference strains Candida albicans ATCC 90028, Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, and Aspergillus flavus ATCC 204304 were included as control isolates for the Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee on Clinical Laboratory Standards [NCCLS]) testing method.
Antifungal Agents
The methodology, as described in the CLSI document M38-A reference, was followed for broth dilution antifungal susceptibility testing of filamentous fungi. Additive drug dilutions were prepared to yield twice the final strength required for the test. Stock solutions of amphotericin B and natamycin at their final concentrations were frozen at 280°C until needed. The agents evaluated in this study have wellestablished microdilution minimum inhibitory concentration (MIC) ranges for these quality control strains (M38-A). Thirty isolates were also sent to the fungal testing laboratory of the University of Texas for voriconazole susceptibility testing and identity confirmation (following CLSI M38-A methodology).
Medical Records Review
After approval from the institutional review board, the medical records of 50 of the 52 affected patients were available for review. All patients included in the chart review had positive corneal culture results for Fusarium sp growth or positive culture from CL paraphernalia plus clinical and confocal microscopy appearance of filamentous fungal corneal infection.
The follow-up best-corrected visual acuity (BCVA) of patients who underwent penetrating keratoplasty (PK) was the last BCVA measured before the surgery. For this group of patients, the time to cure was assigned as an estimate, which was the longest time to cure among clinically treated patients.
The follow-up BCVA of the patients treated with topical or oral antimicrobial agents was the visual acuity measured when the patient was considered cured (inactive corneal scar with intact epithelium). Snellen visual acuities were converted to logarithm of the minimum angle of resolution (logMAR) by the following formula: logMAR acuity = minus log (numerator Snellen/denominator Snellen) for the purpose of data analysis. Vision levels classified as count fingers, hand motion, light perception, and no light perception were assigned Snellen acuities of 1/200, 5/200, 20/20,000, and 20/200,000. The corresponding logMAR visual acuities were 2.3, 2.6, 3.0, and 4.0, respectively, similar to a previously published scale. 30 Statistical analyses were performed using SPSS software version 15.0 (SPSS, Inc, Chicago, IL). Tests of significance were 2 tailed with P # 0.05 for all tests. Univariate comparisons between F. solani and species other than F. solani were performed using the 2-sided Student t test for continuous variables. Nonparametric tests (Mann-Whitney U test) were used for analyzing the data that did not follow normal distribution. Fisher exact test or x 2 test was performed for categorical variables. Analysis of variance was performed for multiple comparisons.
RESULTS
Microbiologic and Molecular Identification
Identification of the organisms as belonging to the Fusarium genus took a mean of 3.6 (62.9) days, with a range of 2 to 12 days, whereas identification to the species level using microbiologic techniques required a mean of 8 (63.7) days.
Molecular identification took up to 24 hours to identify the isolates to the species level. Based on genotype, the 58 isolates were classified into 1 of 5 groups: F. solani species complex (75%), F. oxysporum species complex (16%), F. incarnatumequiseti species complex (5%), F. dimerum species complex (2%), and Fusarium species not otherwise identified (2%). Sequence analysis showed 15 distinct sequences among the 58 isolates. For the purposes of data analysis, and because of the homogeneity of isolate characteristics, the isolates were divided into 2 groups: F. solani and F. non-solani, which includes all species other than F. solani.
Clinical Characteristics and Epidemiology
The 58 samples were isolated from 52 eyes of 52 patients. The clinical characteristics are shown in Table 1 . The follow-up time in this study had a mean of 7.3 (66) months, ranging from 15 days to 24 months. The time from the onset of symptoms until the first evaluation at the Bascom Palmer Eye Institute ranged from 1 day to 33 days, with a mean of 6.6 (67.1) days. No patients had additional pathology at baseline that accounted for decreased visual acuity at any time during the management.
The infiltrates involved the central 6 mm of the cornea in 36 of 50 patients, with no difference observed between F. solani (71%) and F. non-solani (75%) isolates. Compared with peripheral infiltrates, central infiltrates were associated with a statistically significantly worse initial BCVA (20/235 and 20/33, respectively; P , 0.001, t test) and final BCVA (20/142 and 20/28, respectively; P = 0.001, t test).
Risk Factors
Risk factors for infectious keratitis were found in 49 patients (Fig. 1) . Among the 38 patients with F. solani infection, 24 were CL wearers (63%), and among the 12 patients with F. non-solani infection, 9 were CL wearers (75%). The frequency of trauma history between F. solani and F. non-solani infections was similar (20%) in both the groups. Three patients had a history of topical steroid use (2 in the F. solani and 1 in the F. non-solani group).
Management
Complete information for the treatment protocols was present in the records of 48 patients. Both topical and systemic antimicrobial agents were used for the treatment of these infections. Topical natamycin 5% (Natacyn; Alcon Labs, Fort Worth, TX) was used in 41 patients, and it was used as monotherapy in 26 patients and in combination with other antimicrobial agents in 15 patients. Topical voriconazole 1% (compounded from Vfend; Pfizer, Inc, New York, NY) was prescribed for 7 patients, 100 mg of oral fluconazole (generic fluconazole; Cipla Pharmaceuticals, Mumbai, India) twice daily for 6 patients, topical amphotericin B 0.15% (compounded from generic amphotericin B; X-Gen Pharmaceuticals, Inc, Big Flats, NY) for 4 patients, moxifloxacin 0.5% (Vigamox; Alcon Labs) for 3 patients, combination of fortified cefazolin 5% (compounded from generic cefazolin; Abraxis BioScience, Los Angeles, CA) with tobramycin 1.4% (compounded from Ak-Tob 0.3% from Akorn, Lake Forest, IL + generic tobramycin, from Hospira Pharmaceuticals, Lake Forest, IL) for 3 patients each, and 500 mg of oral valacyclovir (Valtrex; GlaxoSmithKline, London, United Kingdom) 3 times per day for 1 patient.
Therapeutic PK was necessary in 7 patients, all of which were caused by F. solani isolates. The time from diagnosis to PK ranged from 4 to 57 days, with a mean of 28 (622) days. The indications for PK were perforation in 4 patients and severe infiltrates nonresponsive to clinical therapy in 3 patients. Four of the therapeutic grafts failed (3 as 
Outcomes
Treatment delay (Fig. 2 ) and time to cure (Fig. 3 ) had a significant correlation with the follow-up BCVA of F. solani versus F. non-solani isolates. Among the 26 patients who received natamycin as monotherapy, 22 (85%) ended with BCVA $ 20/40, and the other 4 patients (15%) had a follow-up BCVA between 20/60 and 20/80 ( Table 2) .
Natamycin was used as a combined therapy in 15 patients, among which natamycin with azoles was used in 11 patients. Eight of these patients (73%) underwent PK or had 
Antifungal Susceptibility Testing
MICs for 50% and 90% of the isolates (MIC 50 and MIC 90 ), medians, and MIC ranges for F. solani and F. nonsolani isolates are listed in Table 3 . In general, the isolates were equally susceptible to natamycin and amphotericin B. F. solani organisms had significantly higher voriconazole MIC values than F. non-solani organisms.
DISCUSSION
A wide spectrum of Fusarium is known to be pathogenic in the human eye. Our improved understanding of this spectrum begs the questions we set forth to address in this study, namely, to determine clinical characteristics and antifungal susceptibilities within the Fusarium genus. Currently, the literature describing these relationships is sparse. Defining these inherent qualities is critical to determining the clinical significance of accurate and rapid species identification.
Clinical Characteristics and Outcomes
In this study, F. solani isolates were associated with significantly longer treatment course (P = 0.035, Mann-Whitney U test), worse follow-up BCVA (P = 0.01, t test), and higher necessity for PK compared with F. non-solani isolates. These observations suggest an increased pathogenicity and differences between in vitro and in vivo antifungal susceptibility among F. solani isolates compared with other species within the genus.
Interestingly, F. solani isolates were associated with poorer outcomes compared with other species of Fusarium, despite slight differences between in vitro susceptibilities for the most commonly available and used topical antifungal agents (natamycin and amphotericin B). This observation suggests that other factors may be responsible for this discordance between in vitro and in vivo antifungal activities, like interspecies differences in pathogenicity.
Systemically, F. solani organisms are significantly more pathogenic and incur a higher risk of mortality compared with F. non-solani isolates. 31 The suggestion of enhanced pathogenicity among F. solani isolates (compared with other Fusarium species) observed in our study, as well as in other nonocular studies, may be explained by species-specific differences in virulence strategies, including organism adherence to the ocular surface, 32 invasion of the organism into the corneal stroma, 33 or alteration of host and pathogen defense mechanisms. 34 
Antifungal Susceptibility
The increasing use of DNA-based identification schemes to accurately and rapidly identify fungal organisms to the species level has brought to light the importance of defining specific antifungal susceptibility profiles. This is particularly important for the Fusarium genus, for which MICs are higher and more variable than for other molds (eg, Aspergillus sp). 23, 26, 27 The results of the in vitro susceptibility tests from the isolates in this study (Tables 2, 3 ) demonstrated high levels of in vitro resistance among Fusarium sp to available antifungal agents, particularly when compared with published susceptibility profiles of other filamentous fungi, including Aspergillus sp and Paecilomyces sp. 26, [35] [36] [37] [38] Across the Fusarium genus, amphotericin B had the lowest MIC values. Finally, different patterns of susceptibility were noted among the different To the present date, 6 studies have explored in vitro antifungal susceptibility patterns among genetically characterized Fusarium isolates. 26, 27, [37] [38] [39] [40] These studies consistently demonstrate variable MICs and high levels of resistance across the spectrum of antifungal agents.
Repeatedly, F. solani isolates have been reported to exhibit greater resistance to antifungal agents than F. non-solani in studies using both morphologic identification 23, 25, [41] [42] [43] [44] [45] and molecular characterization. [37] [38] [39] Among the studies using reliable molecular identification techniques to characterize the isolates, [37] [38] [39] F. solani isolates demonstrated higher levels of resistance to voriconazole, posaconazole, and pentamidine when compared with other species of the Fusarium genus.
Management
In the present study, 11 patients received a combined therapy of natamycin and azoles. A statistically significant number of patients in this group experienced a worse outcome (follow-up BCVA ,20/40 and loss of $2 lines of BCVA) when compared with the other groups (P , 0.001 and 0.032, x 2 test, respectively). Alternatively, the patients who underwent combination therapy may have had more severe disease, which was not reflected by the visual acuity. Of note, it has been demonstrated that combination treatment may produce antagonistic interactions in vitro, particularly when natamycin is used in combination with azoles. 46 
Limitations of the Study
The lower prevalence of F. non-solani, when compared with F. solani infections, did not allow for the selection of an even distribution of Fusarium species to be genotyped. In future studies, an equal distribution and a larger number of isolates from all species would provide more power for further interspecies comparisons. Furthermore, because of the inherent limitations of a retrospective study, the clinical data were incomplete in some cases, specifically risk factor assessment and follow-up information.
CONCLUSIONS
This study demonstrates important differences in antifungal susceptibility profiles and clinical characteristics among Fusarium isolates causing keratitis and suggests that interspecies differences in virulence mechanisms are yet to be explored. Future studies comparing in vitro and in vivo antifungal activity of the available antifungal agents alone and in combination will allow us to accurately assess drug interactions and optimize specific treatment strategies. Furthermore, this study suggests that accurate species identification, especially if performed with rapid polymerase chain reaction techniques, may yield important prognostic and therapeutic information that can influence management decisions and improve patient outcomes in the setting of Fusarium keratitis.
